NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced today that, pursuant to agreements dated February 23 2009 and May 10 2009, it has completed the private allocation of common stock and warrants to ten investors. The placement resulted in gross proceeds to Kamada of approximately US$10 million.
